Literature DB >> 22734081

64 multidetector CT findings of influenza A (H1N1) virus in patients with hematologic malignancies.

Adel El-Badrawy1, Amany Zeidan, Mohamed A Ebrahim.   

Abstract

BACKGROUND: The pandemic of swine-origin H1N1 influenza that began in early 2009 has provided evidence that radiology can assist in the early diagnosis of severe cases. Immunocompromised patients are at increased risk for morbidity and mortality. MDCT is superior to radiography in showing the distribution of the disease.
PURPOSE: To review the 64 multidetector CT thoracic findings of novel swine-origin influenza A (H1N1) virus in patients with hematologic malignancies.
MATERIAL AND METHODS: This study included 12 patients (3 women, 9 men; mean age, 32.2 years). All patients proved to be infected with influenza A (H1N1) virus. The hematologic malignancies were acute myeloid leukemia (n = 8), chronic lymphocytic leukemia (n = 2), multiple myeloma (n = 1), and myelodysplastic syndrome (n = 1). All the patients underwent CT scanning using a 64 multidetector CT scanner. Chest CT scans were reviewed for ground-glass opacities (GGOs), consolidation, airway thickening/dilatation, nodules, mediastinal lymphadenopathy, and pleural effusion.
RESULTS: More than one CT finding was detected in every patient. Pulmonary affection was bilateral, more on the left side. The affections were mainly peribronchial. Airway wall thickening and dilatation were detected in all 12 patients, GGO in 9/12 patients, nodules in 6/12 patients, consolidation in 6/12 patients, hilar lymphadenopathy in 3/12 patients, and pleural effusion in 2/12 patients.
CONCLUSION: Acute myeloid leukemia is the most common hematologic malignancy affected by influenza A (H1N1) virus. The left lung is affected more than the right one. The most common multidetector CT findings are unilateral or bilateral airway thickening and dilatation. Multidetector CT can be used for early and accurate assessment of pulmonary affection with influenza A H1N1 virus infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22734081     DOI: 10.1258/ar.2012.120038

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  6 in total

1.  Hematologic neoplasms: interpreting lung findings in chest computed tomography.

Authors:  P Calvillo Batllés; J Carreres Polo; J Sanz Caballer; M Salavert Lletí; L Compte Torrero
Journal:  Radiologia       Date:  2015-08-24

Review 2.  Current methods and prospects of coronavirus detection.

Authors:  Jiaqi Bu; Zhiwei Deng; Hui Liu; Jiacheng Li; Yanjing Yang; Shian Zhong
Journal:  Talanta       Date:  2020-12-31       Impact factor: 6.556

3.  Chest multidetector computed tomography imaging of COVID-19 pneumonia patients with hematologic malignancies.

Authors:  Adel El-Badrawy; Nada Elbadrawy
Journal:  Blood Res       Date:  2022-08-03

4.  CT findings in viral lower respiratory tract infections caused by parainfluenza virus, influenza virus and respiratory syncytial virus.

Authors:  Min-Chul Kim; Mi Young Kim; Hyun Joo Lee; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Jun Hee Woo; Sung-Han Kim
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

Review 5.  Community acquired respiratory virus infections in cancer patients-Guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for haematology and Medical Oncology.

Authors:  Marie von Lilienfeld-Toal; Annemarie Berger; Maximilian Christopeit; Marcus Hentrich; Claus Peter Heussel; Jana Kalkreuth; Michael Klein; Matthias Kochanek; Olaf Penack; Elke Hauf; Christina Rieger; Gerda Silling; Maria Vehreschild; Thomas Weber; Hans-Heinrich Wolf; Nicola Lehners; Enrico Schalk; Karin Mayer
Journal:  Eur J Cancer       Date:  2016-09-25       Impact factor: 9.162

6.  Longitudinal changes of pneumonia complicating novel influenza A (H1N1) by high-resolution computed tomography.

Authors:  Feng Feng; Ganlin Xia; Yuxin Shi; Zhiyong Zhang
Journal:  Radiol Infect Dis       Date:  2015-06-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.